SG171928A1 - Ethanamine compounds and their use for treating depression - Google Patents

Ethanamine compounds and their use for treating depression Download PDF

Info

Publication number
SG171928A1
SG171928A1 SG2011040342A SG2011040342A SG171928A1 SG 171928 A1 SG171928 A1 SG 171928A1 SG 2011040342 A SG2011040342 A SG 2011040342A SG 2011040342 A SG2011040342 A SG 2011040342A SG 171928 A1 SG171928 A1 SG 171928A1
Authority
SG
Singapore
Prior art keywords
compound
pharmaceutically acceptable
methyl
propan
pyridin
Prior art date
Application number
SG2011040342A
Other languages
English (en)
Inventor
Michael Balestra
Peter Bernstein
Glen E Ernst
William Frietze
John P Mccauley
David Nugiel
Lihong Shen
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42288011&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG171928(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of SG171928A1 publication Critical patent/SG171928A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C07C57/15—Fumaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Confectionery (AREA)
SG2011040342A 2008-12-24 2009-12-22 Ethanamine compounds and their use for treating depression SG171928A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14067308P 2008-12-24 2008-12-24
PCT/SE2009/051493 WO2010074647A1 (en) 2008-12-24 2009-12-22 Ethanamine compounds and their use for treating depression

Publications (1)

Publication Number Publication Date
SG171928A1 true SG171928A1 (en) 2011-07-28

Family

ID=42288011

Family Applications (2)

Application Number Title Priority Date Filing Date
SG2011040342A SG171928A1 (en) 2008-12-24 2009-12-22 Ethanamine compounds and their use for treating depression
SG2013053749A SG192510A1 (en) 2008-12-24 2009-12-22 Ethanamine compounds and their use for treating depression

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG2013053749A SG192510A1 (en) 2008-12-24 2009-12-22 Ethanamine compounds and their use for treating depression

Country Status (31)

Country Link
US (4) US8013165B2 (enExample)
EP (2) EP2391606A4 (enExample)
JP (1) JP5491524B2 (enExample)
KR (1) KR20110097996A (enExample)
CN (1) CN102333762B (enExample)
AR (1) AR074981A1 (enExample)
AU (1) AU2009330745B2 (enExample)
BR (1) BRPI0923476A2 (enExample)
CA (1) CA2748235A1 (enExample)
CL (1) CL2011001590A1 (enExample)
CO (1) CO6450688A2 (enExample)
CR (1) CR20110365A (enExample)
CU (1) CU24017B1 (enExample)
DO (1) DOP2011000205A (enExample)
EA (1) EA201190064A1 (enExample)
EC (1) ECSP11011161A (enExample)
GT (1) GT201100186A (enExample)
HN (1) HN2011001773A (enExample)
IL (1) IL213518A0 (enExample)
MX (1) MX2011006680A (enExample)
NI (1) NI201100131A (enExample)
NZ (1) NZ593282A (enExample)
PE (1) PE20120249A1 (enExample)
SA (1) SA109310013B1 (enExample)
SG (2) SG171928A1 (enExample)
SV (1) SV2011003962A (enExample)
TW (1) TWI442922B (enExample)
UA (1) UA106056C2 (enExample)
UY (1) UY32360A (enExample)
WO (1) WO2010074647A1 (enExample)
ZA (1) ZA201105441B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20110097996A (ko) * 2008-12-24 2011-08-31 아스트라제네카 아베 에탄아민 화합물 및 우울증의 치료를 위한 그의 용도
CN112279843B (zh) * 2020-11-24 2023-05-16 深圳市第二人民医院(深圳市转化医学研究院) 一种具有抗抑郁活性的含氮杂环化合物
CN112250676B (zh) * 2020-11-24 2023-05-16 深圳市第二人民医院(深圳市转化医学研究院) 一种具有抗抑郁活性的含氧杂环化合物

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3422191A (en) 1965-01-21 1969-01-14 Synergistics Inc Compositions and methods for tranquilization employing salts of n-morpholine ethanol
GB1427026A (en) 1972-11-20 1976-03-03 Ici Ltd Synthetic film materials
JPS5756474B2 (enExample) 1973-05-26 1982-11-30
GB9320273D0 (en) 1993-04-01 1993-11-17 Fisons Corp Compound useful in therapy
US5455259A (en) 1987-02-06 1995-10-03 Fisons Corporation Compounds for the treatment of neurodegenerative disorders
ES2083972T3 (es) 1988-08-12 1996-05-01 Astra Ab Arilalquil-aminas y -amidas con propiedades anticonvulsivas y neuroprotectoras.
JP2514855B2 (ja) 1990-08-08 1996-07-10 キッセイ薬品工業株式会社 光学活性なアラニンアニリド誘導体の酸付加塩
US5206248A (en) 1992-03-27 1993-04-27 Smith Richard A Method for reducing emotional lability
ES2142320T3 (es) 1991-10-30 2000-04-16 Astra Ab Derivados de 2-pirazinil-etilamina y su uso como productos farmaceuticos.
NZ251384A (en) * 1992-04-03 1996-10-28 Fisons Corp (s)-enantiomer of 1-phenyl-2-(2-pyridinyl) ethylamine and medicaments
DK0898566T3 (da) * 1996-04-19 2003-03-03 Akzo Nobel Nv Substituerede benzylaminer og anvendelse deraf til behandling af depression
ATE229004T1 (de) 1997-03-31 2002-12-15 Korea Res Inst Chem Tech Chinolinische sulfid-derivate als nmda rezeptor- antagonisten und verfahren zu ihrer herstellung
TW544448B (en) 1997-07-11 2003-08-01 Novartis Ag Pyridine derivatives
SE9901077D0 (sv) * 1999-03-23 1999-03-23 Astra Ab Novel use
SE9901340D0 (sv) 1999-04-15 1999-04-15 Astra Pharma Prod Novel process
DE10334188B4 (de) * 2003-07-26 2007-07-05 Schwarz Pharma Ag Verwendung von Rotigotin zur Behandlung von Depressionen
KR20110097996A (ko) 2008-12-24 2011-08-31 아스트라제네카 아베 에탄아민 화합물 및 우울증의 치료를 위한 그의 용도

Also Published As

Publication number Publication date
CA2748235A1 (en) 2010-07-01
US8013165B2 (en) 2011-09-06
EP2391606A1 (en) 2011-12-07
CU20110141A7 (es) 2012-01-31
US20120277272A1 (en) 2012-11-01
EP2610246A1 (en) 2013-07-03
EA201190064A1 (ru) 2012-02-28
CR20110365A (es) 2011-08-09
ECSP11011161A (es) 2011-07-29
GT201100186A (es) 2013-10-08
ZA201105441B (en) 2012-03-28
CU24017B1 (es) 2014-07-30
US20130137731A1 (en) 2013-05-30
EP2391606A4 (en) 2012-06-13
PE20120249A1 (es) 2012-04-19
SV2011003962A (es) 2012-01-06
CL2011001590A1 (es) 2012-06-22
DOP2011000205A (es) 2011-07-15
SA109310013B1 (ar) 2013-07-28
NZ593282A (en) 2013-06-28
BRPI0923476A2 (pt) 2016-01-19
JP5491524B2 (ja) 2014-05-14
US9035065B2 (en) 2015-05-19
AU2009330745B2 (en) 2012-04-05
NI201100131A (es) 2012-03-19
IL213518A0 (en) 2011-07-31
JP2012513993A (ja) 2012-06-21
MX2011006680A (es) 2011-07-12
AR074981A1 (es) 2011-03-02
WO2010074647A1 (en) 2010-07-01
CN102333762A (zh) 2012-01-25
SG192510A1 (en) 2013-08-30
UA106056C2 (uk) 2014-07-25
TWI442922B (zh) 2014-07-01
HN2011001773A (es) 2014-08-18
CN102333762B (zh) 2014-06-11
TW201028149A (en) 2010-08-01
UY32360A (es) 2010-07-30
AU2009330745A1 (en) 2011-08-04
CO6450688A2 (es) 2012-05-31
US20100179199A1 (en) 2010-07-15
US20120115913A1 (en) 2012-05-10
KR20110097996A (ko) 2011-08-31

Similar Documents

Publication Publication Date Title
EP1966158B1 (en) Substituted cinnoline derivatives as gabaa-receptor modulators and method for their synthesis
EP2303872A1 (en) Isoxazole derivatives and their use as metabotropic glutamate receptor potentiators
US20090221642A1 (en) Muscarinic receptor agonists, compositions, methods of treatment thereof, and processes for preparation thereof-176
AU2009330745B2 (en) Ethanamine compounds and their use for treating depression
WO2018079862A1 (en) Mglur7 modulators
HK1186188A (en) Ethanamine compounds and methods of using the same
AU2012203913A1 (en) Ethanamine compounds and their use for treating depression
US10308635B2 (en) 1-sulfonyl piperidine derivatives as modulators of prokineticin receptors
WO2009105026A1 (en) Compound (r) -n*6*-ethyl-6, 7-dihydro-5h-indeno (5, 6- d) thiazole-2, 6-diamine and the use as antipsychotics
US5700941A (en) Octahydronaphthyridine derivatives
JPH02290878A (ja) ベンゾチエノ（フロ）ピリジン誘導体
GB2299582A (en) Octahydronaphthyridine derivatives